peripheral t cell lymphoma
Showing 1 - 25 of 35
Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CHOP+selinexor+5-Azacitidine
- +2 more
- (no location specified)
Dec 29, 2022
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Aug 17, 2022
Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)
Recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone liposome、Chidamide、Azacitidine
-
Zhejiang, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022
Peripheral T Cell Lymphoma Trial in France (Chemotherapy + follow up, Chemotherapy + ASCT + follow up)
Recruiting
- Peripheral T Cell Lymphoma
- Chemotherapy + follow up
- Chemotherapy + ASCT + follow up
-
Amiens, France
- +47 more
Aug 2, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
May 11, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
May 3, 2022
Peripheral T Cell Lymphoma Trial in Korea, Republic of, United States (lacutamab)
Recruiting
- Peripheral T Cell Lymphoma
- lacutamab
-
Birmingham, Alabama
- +18 more
Apr 4, 2022
Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Mar 4, 2022
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Feb 14, 2022
Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Nanjing (Chidamide)
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Dec 30, 2021
Peripheral T Cell Lymphoma, Relapse/Recurrence Trial in Belgium, France (Lacutamab, Gemcitabine, Oxaliplatine)
Recruiting
- Peripheral T Cell Lymphoma
- Relapse/Recurrence
- Lacutamab
- +2 more
-
Antwerpen, Belgium
- +38 more
Dec 6, 2021
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Sep 29, 2021
Peripheral T Cell Lymphoma Trial in Ann Arbor, Columbus, Madison (Nivolumab, cabiralizumab)
Active, not recruiting
- Peripheral T Cell Lymphoma
-
Ann Arbor, Michigan
- +2 more
Aug 13, 2021
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma Trial in San Francisco, Valhalla (Methotrexate, pralatraxate,,
Recruiting
- NK-Cell Lymphoma
- +2 more
- Methotrexate
- +9 more
-
San Francisco, California
- +1 more
Sep 1, 2021
Treatment-naïve, Peripheral T Cell Lymphoma Trial in Guangzhou (Dose-finding stage: Liposomal mitoxantrone HCl,
Recruiting
- Treatment-naïve
- Peripheral T Cell Lymphoma
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 26, 2021
Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Lymphoma Trial in Shanghai (anti-TRBC1 CAR-T cell
Recruiting
- Peripheral T Cell Lymphoma
- +4 more
- anti-TRBC1 CAR-T cell therapy
-
Shanghai, Shanghai, ChinaXianmin Song
Mar 31, 2021
Peripheral T Cell Lymphoma Trial in Beijing (GB226)
Recruiting
- Peripheral T Cell Lymphoma
- GB226
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Mar 2, 2021
Peripheral T Cell Lymphoma Trial in Guangzhou (Mitoxantrone Hydrochloride Liposome Injection, Chidamide)
Not yet recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Dec 11, 2020
Peripheral T Cell Lymphoma Trial in Hangzhou (Bortezomib, Etoposide, Cyclophosphamide)
Unknown status
- Peripheral T Cell Lymphoma
- Bortezomib
- +4 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Aug 18, 2019
Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in Wuhan (Anti-CD30
Recruiting
- Adult T-Cell Lymphoma/Leukaemia
- +5 more
- Anti-CD30 CAR T cells
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 5, 2019